A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial
To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. Patients aged 18-65 years with RRMS who fulfilled the eligibility crit...
Gespeichert in:
| Veröffentlicht in: | Noro-Psikiyatri Arsivi 2019-12, Vol.56 (4), p.253-257 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 257 |
|---|---|
| container_issue | 4 |
| container_start_page | 253 |
| container_title | Noro-Psikiyatri Arsivi |
| container_volume | 56 |
| creator | Demır, Gülşen Akman Türkoğlu, Recai Saıp, Sabahattin Yüceyar, Nur Efendı, Hüsnü Turan, Ömer Faruk Ağan, Kadriye Terzı, Murat Boz, Cavit Tuncer, Aslı Koçer, Belgin Kasap, Mithat Çalişkan, Zeynep |
| description | To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.
Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life.
Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p |
| doi_str_mv | 10.5152/npa.2017.20515 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6927087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A610934257</galeid><sourcerecordid>A610934257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-e1204480e1e48a161058ae63642d7f3f8dc1efa59f2329d3d2db8f42d87f78233</originalsourceid><addsrcrecordid>eNptUl1LHDEUHaRFrfraxxIolD4423zMR-alsMhuK2yruPY5ZGdudiOZZJxkBP9Vf2IzU7VaJHCT3JxzLvfmJMl7gmc5yekX28kZxaSMId73kkPCcJVmvCjeTGec4qIoD5J33t9gXDBOyv3kgJEKM8zoYfJ7jghNW2fD7hRddGDRSm7AnKIfgwm6BhugR5fauIDWYWju0eJOmkEGbbdoGYMzunUNuu5BhjaikbYoUlqPnEKXETfm1nH3StZBOzsCrsDIzo8SV9DqMIlN9ToDaF0b6J3X_pHuUYqW5z8XsYiW5jh5q6TxcPKwHyW_lovrs-_p6uLb-dl8ldZZSUIKhOIs4xgIZFySguCcSyhYkdGmVEzxpiagZF4pymjVsIY2G67iIy9VySljR8nXv7rdsGmhGSfRSyO6XreyvxdOavHyxeqd2Lo7UVS0xLyMAp8fBHp3O4APotW-BmOkBTd4EWuwitF8gn78D3rjht7G9gTNGOEsz3L-D7WVBoS2ysW69Sgq5rG_imU0H7Vmr6DiauKoa2dB6Zh_Qfj0jLADacLOOzOMn-VfVa7j9_ge1NMwCBajGUU0oxjNKCYzRsKH5yN8gj-6j_0BNN_aFg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2431835458</pqid></control><display><type>article</type><title>A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Demır, Gülşen Akman ; Türkoğlu, Recai ; Saıp, Sabahattin ; Yüceyar, Nur ; Efendı, Hüsnü ; Turan, Ömer Faruk ; Ağan, Kadriye ; Terzı, Murat ; Boz, Cavit ; Tuncer, Aslı ; Koçer, Belgin ; Kasap, Mithat ; Çalişkan, Zeynep</creator><creatorcontrib>Demır, Gülşen Akman ; Türkoğlu, Recai ; Saıp, Sabahattin ; Yüceyar, Nur ; Efendı, Hüsnü ; Turan, Ömer Faruk ; Ağan, Kadriye ; Terzı, Murat ; Boz, Cavit ; Tuncer, Aslı ; Koçer, Belgin ; Kasap, Mithat ; Çalişkan, Zeynep ; Fine Study Group</creatorcontrib><description>To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.
Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life.
Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related.
Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.</description><identifier>ISSN: 1300-0667</identifier><identifier>EISSN: 1309-4866</identifier><identifier>DOI: 10.5152/npa.2017.20515</identifier><identifier>PMID: 31903032</identifier><language>eng</language><publisher>Turkey: AVES</publisher><subject>B cells ; Clinical trials ; Comparative literature ; Demography ; Disease ; FDA approval ; Fingolimod ; Health ; Health surveys ; Medical research ; Multiple sclerosis ; Neurodegeneration ; Patient compliance ; Patient satisfaction ; Quality of life ; Questionnaires ; Recurrence (Disease) ; Statistical analysis ; Surveys</subject><ispartof>Noro-Psikiyatri Arsivi, 2019-12, Vol.56 (4), p.253-257</ispartof><rights>Copyright: © 2019 Turkish Neuropsychiatric Society.</rights><rights>COPYRIGHT 2019 AVES</rights><rights>Copyright BAYT Ltd. Co. Dec 2019</rights><rights>Copyright: © 2019 Turkish Neuropsychiatric Society 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927087/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927087/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31903032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Demır, Gülşen Akman</creatorcontrib><creatorcontrib>Türkoğlu, Recai</creatorcontrib><creatorcontrib>Saıp, Sabahattin</creatorcontrib><creatorcontrib>Yüceyar, Nur</creatorcontrib><creatorcontrib>Efendı, Hüsnü</creatorcontrib><creatorcontrib>Turan, Ömer Faruk</creatorcontrib><creatorcontrib>Ağan, Kadriye</creatorcontrib><creatorcontrib>Terzı, Murat</creatorcontrib><creatorcontrib>Boz, Cavit</creatorcontrib><creatorcontrib>Tuncer, Aslı</creatorcontrib><creatorcontrib>Koçer, Belgin</creatorcontrib><creatorcontrib>Kasap, Mithat</creatorcontrib><creatorcontrib>Çalişkan, Zeynep</creatorcontrib><creatorcontrib>Fine Study Group</creatorcontrib><title>A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial</title><title>Noro-Psikiyatri Arsivi</title><addtitle>Noro Psikiyatr Ars</addtitle><description>To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.
Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life.
Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related.
Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.</description><subject>B cells</subject><subject>Clinical trials</subject><subject>Comparative literature</subject><subject>Demography</subject><subject>Disease</subject><subject>FDA approval</subject><subject>Fingolimod</subject><subject>Health</subject><subject>Health surveys</subject><subject>Medical research</subject><subject>Multiple sclerosis</subject><subject>Neurodegeneration</subject><subject>Patient compliance</subject><subject>Patient satisfaction</subject><subject>Quality of life</subject><subject>Questionnaires</subject><subject>Recurrence (Disease)</subject><subject>Statistical analysis</subject><subject>Surveys</subject><issn>1300-0667</issn><issn>1309-4866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptUl1LHDEUHaRFrfraxxIolD4423zMR-alsMhuK2yruPY5ZGdudiOZZJxkBP9Vf2IzU7VaJHCT3JxzLvfmJMl7gmc5yekX28kZxaSMId73kkPCcJVmvCjeTGec4qIoD5J33t9gXDBOyv3kgJEKM8zoYfJ7jghNW2fD7hRddGDRSm7AnKIfgwm6BhugR5fauIDWYWju0eJOmkEGbbdoGYMzunUNuu5BhjaikbYoUlqPnEKXETfm1nH3StZBOzsCrsDIzo8SV9DqMIlN9ToDaF0b6J3X_pHuUYqW5z8XsYiW5jh5q6TxcPKwHyW_lovrs-_p6uLb-dl8ldZZSUIKhOIs4xgIZFySguCcSyhYkdGmVEzxpiagZF4pymjVsIY2G67iIy9VySljR8nXv7rdsGmhGSfRSyO6XreyvxdOavHyxeqd2Lo7UVS0xLyMAp8fBHp3O4APotW-BmOkBTd4EWuwitF8gn78D3rjht7G9gTNGOEsz3L-D7WVBoS2ysW69Sgq5rG_imU0H7Vmr6DiauKoa2dB6Zh_Qfj0jLADacLOOzOMn-VfVa7j9_ge1NMwCBajGUU0oxjNKCYzRsKH5yN8gj-6j_0BNN_aFg</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Demır, Gülşen Akman</creator><creator>Türkoğlu, Recai</creator><creator>Saıp, Sabahattin</creator><creator>Yüceyar, Nur</creator><creator>Efendı, Hüsnü</creator><creator>Turan, Ömer Faruk</creator><creator>Ağan, Kadriye</creator><creator>Terzı, Murat</creator><creator>Boz, Cavit</creator><creator>Tuncer, Aslı</creator><creator>Koçer, Belgin</creator><creator>Kasap, Mithat</creator><creator>Çalişkan, Zeynep</creator><general>AVES</general><general>BAYT Ltd. Co</general><general>Noro-Psikiyatri Arsivi</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191201</creationdate><title>A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial</title><author>Demır, Gülşen Akman ; Türkoğlu, Recai ; Saıp, Sabahattin ; Yüceyar, Nur ; Efendı, Hüsnü ; Turan, Ömer Faruk ; Ağan, Kadriye ; Terzı, Murat ; Boz, Cavit ; Tuncer, Aslı ; Koçer, Belgin ; Kasap, Mithat ; Çalişkan, Zeynep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-e1204480e1e48a161058ae63642d7f3f8dc1efa59f2329d3d2db8f42d87f78233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>B cells</topic><topic>Clinical trials</topic><topic>Comparative literature</topic><topic>Demography</topic><topic>Disease</topic><topic>FDA approval</topic><topic>Fingolimod</topic><topic>Health</topic><topic>Health surveys</topic><topic>Medical research</topic><topic>Multiple sclerosis</topic><topic>Neurodegeneration</topic><topic>Patient compliance</topic><topic>Patient satisfaction</topic><topic>Quality of life</topic><topic>Questionnaires</topic><topic>Recurrence (Disease)</topic><topic>Statistical analysis</topic><topic>Surveys</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Demır, Gülşen Akman</creatorcontrib><creatorcontrib>Türkoğlu, Recai</creatorcontrib><creatorcontrib>Saıp, Sabahattin</creatorcontrib><creatorcontrib>Yüceyar, Nur</creatorcontrib><creatorcontrib>Efendı, Hüsnü</creatorcontrib><creatorcontrib>Turan, Ömer Faruk</creatorcontrib><creatorcontrib>Ağan, Kadriye</creatorcontrib><creatorcontrib>Terzı, Murat</creatorcontrib><creatorcontrib>Boz, Cavit</creatorcontrib><creatorcontrib>Tuncer, Aslı</creatorcontrib><creatorcontrib>Koçer, Belgin</creatorcontrib><creatorcontrib>Kasap, Mithat</creatorcontrib><creatorcontrib>Çalişkan, Zeynep</creatorcontrib><creatorcontrib>Fine Study Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Noro-Psikiyatri Arsivi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Demır, Gülşen Akman</au><au>Türkoğlu, Recai</au><au>Saıp, Sabahattin</au><au>Yüceyar, Nur</au><au>Efendı, Hüsnü</au><au>Turan, Ömer Faruk</au><au>Ağan, Kadriye</au><au>Terzı, Murat</au><au>Boz, Cavit</au><au>Tuncer, Aslı</au><au>Koçer, Belgin</au><au>Kasap, Mithat</au><au>Çalişkan, Zeynep</au><aucorp>Fine Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial</atitle><jtitle>Noro-Psikiyatri Arsivi</jtitle><addtitle>Noro Psikiyatr Ars</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>56</volume><issue>4</issue><spage>253</spage><epage>257</epage><pages>253-257</pages><issn>1300-0667</issn><eissn>1309-4866</eissn><abstract>To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.
Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life.
Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related.
Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.</abstract><cop>Turkey</cop><pub>AVES</pub><pmid>31903032</pmid><doi>10.5152/npa.2017.20515</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1300-0667 |
| ispartof | Noro-Psikiyatri Arsivi, 2019-12, Vol.56 (4), p.253-257 |
| issn | 1300-0667 1309-4866 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6927087 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | B cells Clinical trials Comparative literature Demography Disease FDA approval Fingolimod Health Health surveys Medical research Multiple sclerosis Neurodegeneration Patient compliance Patient satisfaction Quality of life Questionnaires Recurrence (Disease) Statistical analysis Surveys |
| title | A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T09%3A35%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%2012-month,%20Open%20Label,%20Multicenter%20Pilot%20Study%20Evaluating%20Fingolimod%20Treatment%20in%20terms%20of%20Patient%20Satisfaction%20in%20Relapsing%20Remitting%20Multiple%20Sclerosis%20Patients%20-%20FINE%20Trial&rft.jtitle=Noro-Psikiyatri%20Arsivi&rft.au=Dem%C4%B1r,%20G%C3%BCl%C5%9Fen%20Akman&rft.aucorp=Fine%20Study%20Group&rft.date=2019-12-01&rft.volume=56&rft.issue=4&rft.spage=253&rft.epage=257&rft.pages=253-257&rft.issn=1300-0667&rft.eissn=1309-4866&rft_id=info:doi/10.5152/npa.2017.20515&rft_dat=%3Cgale_pubme%3EA610934257%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2431835458&rft_id=info:pmid/31903032&rft_galeid=A610934257&rfr_iscdi=true |